<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780804</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2016-00708</org_study_id>
    <secondary_id>NCI-2016-00708</secondary_id>
    <secondary_id>ADVL1513</secondary_id>
    <secondary_id>ADVL1513</secondary_id>
    <secondary_id>ADVL1513</secondary_id>
    <secondary_id>UM1CA097452</secondary_id>
    <nct_id>NCT02780804</nct_id>
  </id_info>
  <brief_title>Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of entinostat in treating pediatric&#xD;
      patients with solid tumors that have come back or have not responded to treatment. Entinostat&#xD;
      may block some of the enzymes needed for cell division and it may help to kill tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose of entinostat&#xD;
      administered as a single-agent, once weekly to children with recurrent or refractory solid&#xD;
      tumors.&#xD;
&#xD;
      II. To define and describe the toxicities of entinostat administered as a single agent, once&#xD;
      weekly to children with recurrent or refractory solid tumors.&#xD;
&#xD;
      III. To characterize the pharmacokinetics of entinostat in children with recurrent or&#xD;
      refractory cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To preliminarily define the antitumor activity of entinostat within the confines of a&#xD;
      phase 1 study.&#xD;
&#xD;
      II. To assess change in histone H3 and H4 acetylation in peripheral blood mononuclear cells&#xD;
      (PBMCs) as a marker of the biologic activity of entinostat.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients receive entinostat orally (PO) on days 1, 8, 15, and 22. Cycles repeat every 28 days&#xD;
      for up to 5 years in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 26, 2016</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Will be defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity during cycle 1 of therapy. Will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Will be described and graded using CTCAE version 5.0. A descriptive summary of all toxicities will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in pharmacokinetic (PK) parameters</measure>
    <time_frame>Pre-dose on days 1, 8, and 22 and 1, 3 ,6, 24, 48 and 96 hours post-dose on day 1, and day 28</time_frame>
    <description>A descriptive analysis of PK parameters of entinostat will be performed to define systemic exposure, drug clearance, and other pharmacokinetic parameters. The PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor activity of entinostat</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in histone H3 and H4 acetylation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be assessed in peripheral blood mononuclear cells.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Brain Stem Neoplasm</condition>
  <condition>Pineal Region Neoplasm</condition>
  <condition>Recurrent Lymphoma</condition>
  <condition>Recurrent Malignant Solid Neoplasm</condition>
  <condition>Recurrent Primary Central Nervous System Neoplasm</condition>
  <condition>Recurrent Visual Pathway Glioma</condition>
  <condition>Refractory Lymphoma</condition>
  <condition>Refractory Malignant Solid Neoplasm</condition>
  <condition>Refractory Primary Central Nervous System Neoplasm</condition>
  <condition>Refractory Visual Pathway Glioma</condition>
  <arm_group>
    <arm_group_label>Treatment (entinostat)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (entinostat)</arm_group_label>
    <other_name>HDAC inhibitor SNDX-275</other_name>
    <other_name>MS 27-275</other_name>
    <other_name>MS-275</other_name>
    <other_name>SNDX-275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (entinostat)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a body surface area (BSA) of &gt;= 1.17 m^2 at time of study&#xD;
             enrollment&#xD;
&#xD;
          -  Patients must be able to swallow intact tablets&#xD;
&#xD;
          -  Patients with recurrent or refractory solid tumors, including central nervous system&#xD;
             (CNS) tumors or lymphoma, are eligible; patients must have had histologic verification&#xD;
             of malignancy at original diagnosis or relapse except in patients with intrinsic brain&#xD;
             stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of&#xD;
             cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or&#xD;
             beta-human chorionic gonadotropin (HCG)&#xD;
&#xD;
          -  Patients must have either measurable or evaluable disease&#xD;
&#xD;
          -  Patient's current disease state must be one for which there is no known curative&#xD;
             therapy or therapy proven to prolong survival with an acceptable quality of life&#xD;
&#xD;
          -  Karnofsky &gt;= 50% for patients &gt; 16 years of age and Lansky &gt;= 50 for patients =&lt; 16&#xD;
             years of age; Note: neurologic deficits in patients with CNS tumors must have been&#xD;
             relatively stable for at least 7 days prior to study enrollment; patients who are&#xD;
             unable to walk because of paralysis, but who are up in a wheelchair, will be&#xD;
             considered ambulatory for the purpose of assessing the performance score&#xD;
&#xD;
          -  Patients must have fully recovered from the acute toxic effects of all prior&#xD;
             anti-cancer therapy and must meet the following minimum duration from prior&#xD;
             anti-cancer directed therapy prior to enrollment; if after the required timeframe, the&#xD;
             defined eligibility criteria are met, e.g. blood count criteria, the patient is&#xD;
             considered to have recovered adequately&#xD;
&#xD;
               -  Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive;&#xD;
                  the duration of this interval must be discussed with the study chair and the&#xD;
                  study-assigned research coordinator prior to enrollment&#xD;
&#xD;
                    -  Solid tumor patients: &gt;= 21 days after the last dose of cytotoxic or&#xD;
                       myelosuppressive chemotherapy (42 days if prior nitrosourea)&#xD;
&#xD;
                    -  Lymphoma patients:&#xD;
&#xD;
                         -  a waiting period prior to enrollment is not required for patients&#xD;
                            receiving standard cytotoxic maintenance chemotherapy (i.e.&#xD;
                            corticosteroid, vincristine, thioguanine[6MP], and/or methotrexate)&#xD;
&#xD;
                         -  &gt;=14 days must have elapsed after the completion of other cytotoxic&#xD;
                            therapy, with the exception of hydroxyurea, for patients not receiving&#xD;
                            standard maintenance therapy; additionally, patients must have fully&#xD;
                            recovered from all acute toxic effects of prior therapy; Note:&#xD;
                            cytoreduction with hydroxyurea must be discontinued &gt;= 24 hours prior&#xD;
                            to the start of protocol therapy&#xD;
&#xD;
               -  Anti-cancer agents not known to be myelosuppressive (e.g. not associated with&#xD;
                  reduced platelet or absolute neutrophil count [ANC] counts): &gt;= 7 days must have&#xD;
                  elapsed from the last dose of agent; the duration of this interval must be&#xD;
                  discussed with the study chair and the study-assigned research coordinator prior&#xD;
                  to enrollment&#xD;
&#xD;
               -  Antibodies: &gt;= 21 days must have elapsed from infusion of last dose of antibody,&#xD;
                  and toxicity related to prior antibody therapy must be recovered to grade =&lt; 1&#xD;
&#xD;
               -  Hematopoietic growth factors: &gt;= 14 days must have elapsed from the last dose of&#xD;
                  a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting&#xD;
                  growth factor; for agents that have known adverse events occurring beyond 7 days&#xD;
                  after administration, this period must be extended beyond the time during which&#xD;
                  adverse events are known to occur; the duration of this interval must be&#xD;
                  discussed with the study chair and the study-assigned research coordinator&#xD;
&#xD;
               -  Interleukins, interferons and cytokines (other than hematopoietic growth&#xD;
                  factors): &gt;= 21 days must have elapsed from the last dose of interleukins,&#xD;
                  interferon or cytokines (other than hematopoietic growth factors)&#xD;
&#xD;
               -  Stem cell infusions (with or without traumatic brain injury [TBI]):&#xD;
&#xD;
                    -  Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem&#xD;
                       cell infusion including donor lymphocyte infusion (DLI) or boost infusion:&#xD;
                       &gt;= 84 days must have elapsed from infusion and no evidence of graft versus&#xD;
                       host disease (GVHD)&#xD;
&#xD;
                    -  Autologous stem cell infusion including boost infusion: &gt;= 42 days must have&#xD;
                       elapsed from infusion&#xD;
&#xD;
               -  Cellular therapy: &gt;= 42 days must have elapsed from last dose of any type of&#xD;
                  cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic&#xD;
                  cells, etc.)&#xD;
&#xD;
               -  External beam radiation (XRT)/external beam irradiation including protons: &gt;= 14&#xD;
                  days must have elapsed after local XRT; &gt;= 150 days after TBI, craniospinal XRT&#xD;
                  or if radiation to 50% of the pelvis; &gt;= 42 days if other substantial bone marrow&#xD;
                  (BM) radiation&#xD;
&#xD;
               -  Radiopharmaceutical therapy (e.g., radiolabeled antibody, iobenguane I-131&#xD;
                  [131I-MIBG]): &gt;= 42 days must have elapsed from the last dose of systemically&#xD;
                  administered radiopharmaceutical therapy&#xD;
&#xD;
               -  Histone deacetylase (HDAC) inhibitors: Patients must not have received prior&#xD;
                  therapy with entinostat; patients who have received therapy with other HDAC&#xD;
                  inhibitors are eligible&#xD;
&#xD;
          -  Peripheral absolute neutrophil count (ANC) &gt;= 1000/mm^3 (within 7 days prior to&#xD;
             enrollment)&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3 (transfusion independent, defined as not receiving&#xD;
             platelet transfusions for at least 7 days prior to enrollment) (within 7 days prior to&#xD;
             enrollment)&#xD;
&#xD;
          -  Hemoglobin &gt;= 8.0 g/dl, with or without transfusion (within 7 days prior to&#xD;
             enrollment)&#xD;
&#xD;
          -  Patients with known bone marrow metastatic disease will not be eligible&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70&#xD;
             ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:&#xD;
&#xD;
               -  1 to &lt; 2 years: 0.6 mg/dL for males and females&#xD;
&#xD;
               -  2 to &lt; 6 years: 0.8 mg/dL for males and females&#xD;
&#xD;
               -  6 to &lt; 10 years: 1.0 mg/dL for males and females&#xD;
&#xD;
               -  10 to &lt; 13 years: 1.2 mg/dL for males and females&#xD;
&#xD;
               -  13 to &lt; 16 years: 1.5 mg/dL for males and 1.4 mg/dL for females&#xD;
&#xD;
               -  &gt; = 16 years: 1.7 mg/dL for males and 1.4 mg/dL for females (within 7 days prior&#xD;
                  to enrollment)&#xD;
&#xD;
          -  Bilirubin (sum of conjugated + conjugated) =&lt; 1.5 x upper limit of normal (ULN) for&#xD;
             age (within 7 days prior to enrollment)&#xD;
&#xD;
          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 3 x&#xD;
             upper limit of normal (ULN) = 135 U/l; for the purpose of this study, the ULN for SGPT&#xD;
             is 45 U/l (within 7 days prior to enrollment)&#xD;
&#xD;
          -  Serum albumin &gt;= 2 g/dl (within 7 days prior to enrollment)&#xD;
&#xD;
          -  All patients and/or their parents or legally authorized representatives must sign a&#xD;
             written informed consent; assent, when appropriate, will be obtained according to&#xD;
             institutional guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women will not be entered on this study; pregnancy tests&#xD;
             must be obtained in girls who are post-menarchal; males or females of reproductive&#xD;
             potential may not participate unless they have agreed to use an effective&#xD;
             contraceptive method both during and for 3 months after participation in this study;&#xD;
             abstinence is an acceptable method of contraception; those who become pregnant while&#xD;
             on treatment with entinostat must discontinue immediately and consult their treating&#xD;
             physician&#xD;
&#xD;
          -  Patients receiving corticosteroids who have not been on a stable or decreasing dose of&#xD;
             corticosteroid for at least 7 days prior to enrollment are not eligible; if used to&#xD;
             modify immune adverse events related to prior therapy, &gt;= 14 days must have elapsed&#xD;
             since last dose of corticosteroid&#xD;
&#xD;
          -  Patients who are currently receiving another investigational drug are not eligible&#xD;
&#xD;
          -  Patients who are currently receiving other anti-cancer agents are not eligible&#xD;
&#xD;
          -  Patients requiring concurrent administration of valproic acid are not eligible for&#xD;
             this trial&#xD;
&#xD;
          -  Patients who are receiving cyclosporine, tacrolimus or other agents to prevent&#xD;
             graft-versus-host disease post bone marrow transplant are not eligible for this trial&#xD;
&#xD;
          -  Patients with a BSA Ë‚ 1.17 m^2 at time of study enrollment are not eligible&#xD;
&#xD;
          -  Patients who are not able to swallow intact tablets are not eligible&#xD;
&#xD;
          -  Patients with a known history of corrected QT (QTc) prolongation (&gt; 480 msec), or&#xD;
             known history of ventricular tachycardia, ventricular fibrillation or Torsades de&#xD;
             pointes are not eligible&#xD;
&#xD;
          -  Patients who have an uncontrolled infection are not eligible&#xD;
&#xD;
          -  Patients who have received a prior solid organ transplantation are not eligible&#xD;
&#xD;
          -  Patients who in the opinion of the investigator may not be able to comply with the&#xD;
             safety monitoring requirements of the study are not eligible&#xD;
&#xD;
          -  Patients with a history of allergy to medications that have a benzamide structure&#xD;
             (e.g., metoclopramide, procarbazine, domperidone, cisapride etc.) are not eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Bukowinski</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Optic Nerve Glioma</mesh_term>
    <mesh_term>Brain Stem Neoplasms</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entinostat</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

